OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
2.860
-0.050 (-1.72%)
Oct 25, 2024, 3:59 PM EDT - Market closed

OS Therapies Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for OS Therapies stock has a target of 21, which predicts an increase of 634.27% from the current stock price of 2.86.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $21 $21 $21 $21
Change +634.27% +634.27% +634.27% +634.27%

Analyst Ratings

According to 1 stock analyst, the rating for OS Therapies is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Sep '24Oct '24
Strong Buy 11
Buy 00
Hold 00
Sell 00
Strong Sell 00
Total 11

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
EF Hutton
EF Hutton
Strong Buy
Maintains
$21
Strong Buy Maintains $21 +634.27% Oct 3, 2024
EF Hutton
EF Hutton
Strong Buy
Maintains
$21
Strong Buy Maintains $21 +634.27% Sep 16, 2024
EF Hutton
EF Hutton
Strong Buy
Initiates
$21
Strong Buy Initiates $21 +634.27% Sep 3, 2024
More Analyst Ratings

Financial Forecast

Revenue This Year
561.00K
Revenue Next Year
56.10M
from 561.00K
Increased by 9,900.00%
EPS This Year
n/a
from -0.74
EPS Next Year
n/a
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026
Revenue
----561.00K56.10M26.88M
Revenue Growth
-----9,900.00%-52.09%
EPS
-0.72-0.75-0.64-0.74---
EPS Growth
-------
Forward PE
-------
No. Analysts ----444
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 202420252026
High 1.2M 115.5M 33.9M
Avg 561,000 56.1M 26.9M
Low n/a n/a 20.0M

Revenue Growth

Revenue Growth 202420252026
High -
20,488.2%
-39.5%
Avg -
9,900.0%
-52.1%
Low - -
-64.4%

EPS Forecast

EPS
High
Avg
Low

EPS Growth

EPS Growth
High
Avg
Low
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.